-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] In recent years, with the rising cost of new drug research and development and the intensification of the domestic pharmaceutical market, the overseas track has gradually entered the field of vision of domestic investo.
Recently, KPMG and GBI jointly released the "White Paper on Chinese Pharmaceutical Companies Going Overseas", which pointed out that in 2020, China's innovative drugs will enter the outbreak period of "going oversea.
A total of 271 cases have been recorded, achieving an increase of 300% in five yea.
For local pharmaceutical companies, turning their attention to overseas markets is undoubtedly a new way out, but the process of “going overseas” is not as simple as imagin.
From some cases of “going overseas” failures, it can be seen that there are many challenges in overseas markets, and pharmaceutical companies are faced with the goal of A series of issues such as national market registration supervision, business and competition, access, investment and tax environme.
Judging from the direction chosen by local pharmaceutical companies to go overseas, the European and American markets are mostly the first stop, which is mainly related to factors such as the high global consensus on the FAD standard, the strong market share of the US market and the relatively free pricing power of innovative dru.
In recent years, there have been many cases where local pharmaceutical companies have applied to the FAD for their produc.
For example, at the end of February this year, Legend Bio's CAR-T therapy Sidaki Aurexa was successfully approved by the FDA for the treatment of relapsed/refractory multiple Myeloma (r/r MM) patients, this is also the second innovative drug successfully launched in the United States after BeiGene's zanubrutin.
It is worth mentioning that the FAD threshold is relatively high and the review system is stri.
Although local pharmaceutical companies have a strong desire to sprint FAD, the actual number of approvals is very limit.
Many pharmaceutical companies include Wanchun, Innovent, and Huang Medicine and others have all failed to break throu.
The industry believes that in addition to the mature markets in Europe and the United States, local pharmaceutical companies can also synthesize their own competitive advantages to find new breakthroughs, such as targeting emerging market countri.
In recent years, the state has successively introduced policies to encourage and support innovative pharmaceutical companies to "go overseas" to emerging market countri.
Emerging markets have untapped and unincorporated market space and potential, while Chinese innovative drugs are generally cost-effective and more suitable for developing countri.
patient nee.
It is understood that many local pharmaceutical companies have turned their targets to emerging market countri.
For example, on June 14, Innovent Bio's innovative drug Dayoutong was approved for marketing in Indonesia for the treatment of metastatic colorectal cancer, ovarian cancer, cervical cancer and other high-incidence tumo.
On June 14, the clinical and commercial cooperation between Kintor and Etana in Indonesia was successfully selected as the “One Belt, One Road” innovation cooperation project as the project of “Clinical Trial Cooperative R&D and Overseas Application Demonstration of Anti-COVID-19 Drug.
Kintor Pharmaceutical stated that the successful establishment of the project marks the recognition of the company's R&D capabilities and innovation cooperati.
On June 13, Henlius announced that it had signed a license and supply agreement with Organon, a subsidiary of Merck & .
, which granted the latter two products except China's Pertuzumab biosimilar HLX11 and denosumab biosimilar HLX1 Exclusive commercialization rights worldwide, including many emerging marke.
Henlius will receive $541 million in potential revenue from .
In addition, BeiGene also stated that zanubrutinib has been approved in 50 markets around the world, including many breakthroughs in emerging marke.
It has been approved in Kuwait, Bahrain and Qatar, and continues to expand in the Middle East and North Afri.
However, although the emerging market space is broad enough, different regions have different characteristi.
Local pharmaceutical companies going overseas to emerging market countries may face challenges such as unformed market rules and imperfect pharmaceutical foundatio.
Moving to commercial production continues to explo.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Recently, KPMG and GBI jointly released the "White Paper on Chinese Pharmaceutical Companies Going Overseas", which pointed out that in 2020, China's innovative drugs will enter the outbreak period of "going oversea.
A total of 271 cases have been recorded, achieving an increase of 300% in five yea.
For local pharmaceutical companies, turning their attention to overseas markets is undoubtedly a new way out, but the process of “going overseas” is not as simple as imagin.
From some cases of “going overseas” failures, it can be seen that there are many challenges in overseas markets, and pharmaceutical companies are faced with the goal of A series of issues such as national market registration supervision, business and competition, access, investment and tax environme.
Judging from the direction chosen by local pharmaceutical companies to go overseas, the European and American markets are mostly the first stop, which is mainly related to factors such as the high global consensus on the FAD standard, the strong market share of the US market and the relatively free pricing power of innovative dru.
In recent years, there have been many cases where local pharmaceutical companies have applied to the FAD for their produc.
For example, at the end of February this year, Legend Bio's CAR-T therapy Sidaki Aurexa was successfully approved by the FDA for the treatment of relapsed/refractory multiple Myeloma (r/r MM) patients, this is also the second innovative drug successfully launched in the United States after BeiGene's zanubrutin.
It is worth mentioning that the FAD threshold is relatively high and the review system is stri.
Although local pharmaceutical companies have a strong desire to sprint FAD, the actual number of approvals is very limit.
Many pharmaceutical companies include Wanchun, Innovent, and Huang Medicine and others have all failed to break throu.
The industry believes that in addition to the mature markets in Europe and the United States, local pharmaceutical companies can also synthesize their own competitive advantages to find new breakthroughs, such as targeting emerging market countri.
In recent years, the state has successively introduced policies to encourage and support innovative pharmaceutical companies to "go overseas" to emerging market countri.
Emerging markets have untapped and unincorporated market space and potential, while Chinese innovative drugs are generally cost-effective and more suitable for developing countri.
patient nee.
It is understood that many local pharmaceutical companies have turned their targets to emerging market countri.
For example, on June 14, Innovent Bio's innovative drug Dayoutong was approved for marketing in Indonesia for the treatment of metastatic colorectal cancer, ovarian cancer, cervical cancer and other high-incidence tumo.
On June 14, the clinical and commercial cooperation between Kintor and Etana in Indonesia was successfully selected as the “One Belt, One Road” innovation cooperation project as the project of “Clinical Trial Cooperative R&D and Overseas Application Demonstration of Anti-COVID-19 Drug.
Kintor Pharmaceutical stated that the successful establishment of the project marks the recognition of the company's R&D capabilities and innovation cooperati.
On June 13, Henlius announced that it had signed a license and supply agreement with Organon, a subsidiary of Merck & .
, which granted the latter two products except China's Pertuzumab biosimilar HLX11 and denosumab biosimilar HLX1 Exclusive commercialization rights worldwide, including many emerging marke.
Henlius will receive $541 million in potential revenue from .
In addition, BeiGene also stated that zanubrutinib has been approved in 50 markets around the world, including many breakthroughs in emerging marke.
It has been approved in Kuwait, Bahrain and Qatar, and continues to expand in the Middle East and North Afri.
However, although the emerging market space is broad enough, different regions have different characteristi.
Local pharmaceutical companies going overseas to emerging market countries may face challenges such as unformed market rules and imperfect pharmaceutical foundatio.
Moving to commercial production continues to explo.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.